Key Takeaway: ProKidney has successfully completed patient enrollment for the Phase 3 PROACT 1 study, which is crucial for the accelerated approval efficacy analysis. The company expects to release pivotal eGFR slope topline results in the second quarter of 2027. Additionally, ProKidney is on schedule to finish full enrollment for PROACT 1 in the latter half of 2026.
Market Sentiment Analysis
POSITIVE FACTORS
Completed enrollment for Phase 3 PROACT 1 study.
Anticipated pivotal eGFR slope topline results in Q2 2027.
On track for full enrollment completion in second half of 2026.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
2.5%
average across 4 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
Renal Autologous Cell Therapy
Phase 3 · Type 2 Diabetes Mellitus
Full Press Release Details
Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full enrollment for PROACT 1 in the second half of 2026 Appointed Kenneth
Frequently Asked Questions
What is the PROACT 1 study?
The PROACT 1 study is a Phase 3 clinical trial evaluating the efficacy of ProKidney's treatment.
When will the topline results be available?
Topline results for the eGFR slope are anticipated in Q2 2027.
What enrollment milestones has ProKidney achieved?
ProKidney has completed patient enrollment for the PROACT 1 study.
When is full enrollment expected for PROACT 1?
Full enrollment for PROACT 1 is expected to be completed in the second half of 2026.